common.study.topics.clinical

Adjunctive, Low-Dose tPA in Primary PCI for STEMI

common.study.values.description

Adjunctive, Low-dose tPA in Primary PCI for STEMI

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - tissue plasminogen activator

Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.

Saline

Placebo

participant.views.study.view.additional

participant.views.study.view.scientific-title

Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction

common.study.values.clinical-trial-id

NCT03335839

participant.views.study.view.id

Pe9K4b